Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_assertion type Assertion NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_head.
- NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_assertion description "[Although samples enriched for APOE ?4 carriers in AD or MCI clinical trials showed slightly more cognitive impairment and greater decline using the number APOE ?4 alleles as an inclusion criterion most likely would not result in more efficient trials, and trials would take longer because fewer patients would be available.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_provenance.
- NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_assertion evidence source_evidence_literature NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_provenance.
- NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_assertion SIO_000772 23712001 NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_provenance.
- NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_assertion wasDerivedFrom befree-2016 NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_provenance.
- NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_assertion wasGeneratedBy ECO_0000203 NP1081081.RAeiloVyQ2D383v4PGdKEIpLlR6jQ3Rcbw8CB__MxSomw130_provenance.